scemblix
novartis europharm limited - asciminib hydrochloride - leukæmi, myelogen, kronisk, bcr-abl positiv - antineoplastiske midler - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.
axitinib "stada" 1 mg filmovertrukne tabletter
stada arzneimittel ag - axitinib - filmovertrukne tabletter - 1 mg
axitinib "stada" 3 mg filmovertrukne tabletter
stada arzneimittel ag - axitinib - filmovertrukne tabletter - 3 mg
axitinib "stada" 5 mg filmovertrukne tabletter
stada arzneimittel ag - axitinib - filmovertrukne tabletter - 5 mg
axitinib "stada" 7 mg filmovertrukne tabletter
stada arzneimittel ag - axitinib - filmovertrukne tabletter - 7 mg
masivet
ab science s.a. - masitinib mesilate - antineoplastiske midler - hunde - behandling af ikke-resekterbare hunmastcelletumorer (grad 2 eller 3) med bekræftet muteret c-kit tyrosin-kinase receptor.
inlyta
pfizer europe ma eeig - axitinib - carcinom, nyrecelle - protein kinase hæmmere - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.
masipro
ab science - masitinib mesilate - mastocytose - antineoplastiske midler - behandling af mastocytose.
masiviera
ab science - masitinib - bukspyttkjertel-neoplasmer - protein kinase hæmmere - behandling af ikke resectable lokalt fremskreden eller metastatisk kræft i bugspytkirtlen.
masican
masitinib - gastrointestinale stromale tumorer - protein kinase hæmmere - behandling af inoperabel og/eller metastatisk maligne gastrointestinale stromale tumor (gist).